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REVIEW ARTICLE
Summary. Infections by intracellular pathogens such as viruses, some bacteria
and many parasites, are cleared in most cases after activation of specific T cellular
immune responses that recognize foreign antigens and eliminate infected cells.
Vaccines against those infectious organisms have been traditionally developed by
administration of whole live attenuated or inactivated microorganisms. Nowadays,
research is focused on the development of subunit vaccines, containing the most
immunogenic antigens from the particular pathogen. However, when purified sub-
unit vaccines are administered using traditional immunization protocols, the levels
of cellular immunity induced are mostly low and not capable of eliciting complete
protection against diseases caused by intracellular microbes. In this review, we pres-
ent a promising alternative to those traditional protocols, which is the use of recom-
binant viruses encoding subunit vaccines as immunization tools. Recombinant virus-
es have several interesting features that make them extremely efficient at inducing
immune responses mediated by T-lymphocytes. This cellular immunity has recently
been demonstrated to be of key importance for protection against malaria and AIDS,
both of which are major targets of the World Health Organization for vaccine
development. Thus, this review will focus in particular on the development of new
vaccination protocols against these diseases. [Int Microbiol 2004; 7(2):83–94]
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Introduction
Immunogenic and protective antigens of the causative agents
of malaria (Plasmodium spp.) and AIDS (human immunode-
ficiency virus, HIV), which are two of the major internation-
al targets for vaccine development, have been already identi-
fied. However, the development of vaccines against those
diseases has been hampered in part by the inefficient stimu-
lation of the corresponding protective cellular immune
responses to traditional vaccines, which are based on the
administration of purified antigens. In many cases, these tra-
ditional immunization techniques and protocols do not seem
to result in the triggering of sufficient levels of cellular
immunity required for the elimination of infected cells.
New vehicles for antigen delivery, immunization adju-
vants, and vaccination protocols to improve cellular immun-
ity are currently being tested both in animals and in humans.
Among the new vehicles for antigen delivery, some of the
most promising are vaccines based on recombinant viruses.
These can express the foreign antigens directly inside cells of
the host organism, as would happen in natural infection.
Antigens so expressed are made available to the intracellular
antigen-processing machinery, allowing processing of the
antigen and binding of the resulting fragments to major his-
tocompatibility complex (MHC) molecules, favoring their
presentation to T-lymphocytes (Fig. 1).
The construction of recombinant viruses requires adapta-
tion of the DNA sequences that encode the antigen for
expression in host cells. In many cases, it also requires mul-
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tiple intracellular recombination steps to incorporate the
transgenes into the viral genome. However, although compli-
cated to generate, recombinant viruses have several features
that make them excellent immunogens and vehicles for vac-
cine delivery. First, by nature, viruses have evolved to be the
organisms that most efficiently infect cells. In 10 min, more
than 95% of the initial viral load is in an intracellular form for
some viruses [35]. Second, viral proteins can act as strong
immunization adjuvants [36]. Third, viruses can infect direct-
ly antigen-presenting cells, thereby avoiding unnecessary
cross-presentation steps [4]. In addition, some recombinant
viruses can be lyophilized and stored without the need of spe-
cial refrigeration equipment. As a whole, these and other fea-
tures have enabled the development of immunization proto-
cols based on a single administration of the viral vectors
capable of inducing potent immune responses, which in
many cases completely protect against the respective dis-
eases.
Although almost any viral genome can be manipulated to
become recombinant and acquire the capacity of expressing
foreign antigens in host cells, not all viruses have the same
efficiency in doing so. Certain types have been reported to be
more efficient than others in inducing immune responses.
Among those, poxviruses, adenoviruses, and influenza viruses
are three of the most attractive and efficient vectors that can
be used for vaccination purposes. We will describe the fea-
tures and construction particularities of these three viral vec-
tors, which we have studied for the last several years, as well
as the pros and cons of their use.
In the cases in which immunization with one viral vector
did not elicit sufficient levels of immunity, researchers have
successfully immunized by the sequential administration of
two of these vectors. These immunization protocols are the
so-called prime-boost protocols. Several seminal studies,
first performed in the field of malaria vaccine development
[27,34,39,47], have provided much of the present knowl-
edge on these immunization protocols, and most of the new
vaccines in development apply this technology, especially
when they aim at inducing a strong cellular immune
response against a pathogen. Studies that included these
potent immunization protocols will also be commented on in
this review.
Recombinant poxviruses
Members of the Poxviridae family that infect vertebrates are
divided in eight genera: Avipoxvirus, Capripoxvirus, Lepori-
poxvirus, Molluscipoxvirus, Orthopoxvirus, Parapoxvirus,
Suipoxvirus and Yatapoxvirus. The constituents of a genus
are genetically and antigenically related and have similar
morphologies [12].
Vaccinia virus and other related orthopoxvirus-
es. The Orthopoxvirus is the most studied genus of the
Poxviridae family, having as major representatives the vario-
la and vaccinia viruses. Variola, the agent of smallpox, is
strictly a human virus. In contrast, vaccinia virus, which is
used as a smallpox vaccine, has a wide vertebrate host range
and can therefore serve as vaccine vector in a large variety of
species. Vaccinia virus replicates in vitro and in vivo in vari-
ous species of vertebrates from birds to humans. Nowadays,
however, vaccinia virus has no natural reservoir and it is con-
sidered to be almost exclusively a laboratory virus.
The poxviral genome consists of a linear 130- to 300-kb
double-stranded (ds) DNA and is capable of accepting large
inserts of foreign DNA, making it an excellent vector for
expression of transgenic sequences. The life cycle of
ROCHA ET AL.
Fig. 1. Immune responses induced by recombinant viruses. Recombinant
viruses carrying sequences that code for the desired antigen have several
advantages in inducing cellular immune responses (both CD8 and CD4 T
lymphocytes) against intracellular pathogens: (1) They infect the cells effi-
ciently by nature. (2) The viral proteins may act as vaccination adjuvants. (3)
They express the recombinant products in the cytoplasm of cells of the host
organism as the intracellular pathogen would do in a natural infection; frag-
ments of the recombinant products can then be easily loaded onto MHC mol-
ecules and presented on the surface of the host cells to T-lymphocytes. (4)
They can directly infect antigen-presenting cells, eg. dendritic cells, which
favors initiation of the immune responses. n, Cell nucleus.
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poxviruses is completed within 12–24 h and occurs exclu-
sively within the cytoplasm of the infected cell [38]. A num-
ber of features make poxvirus recombinants good candidates
as vaccine vectors: (i) the stability of freeze-dried vaccines,
its low cost, and the ease of manufacture and administration;
(ii) the cytoplasmic site of gene expression; (iii) the ability to
induce cellular immune responses against the foreign antigen
with long-lasting immunity after a single inoculation; and
(iv) the flexibility of the genome, which allows large amounts
of the genome to be lost or deleted and foreign DNA to be
integrated (over 25 kb) without loss of infectivity.
In 1980, the World Health Organization declared small-
pox eradicated and recommended the discontinuation of vac-
cination with vaccinia. This vaccination, which had been per-
formed for nearly two centuries, consisted of the inoculation
of vaccinia virus intradermically. The immune response to
vaccinia, although a less virulent virus, promotes cross-pro-
tection against smallpox. However, despite the relative safe-
ty of this vaccine, some vaccine-related complications
occurred during the eradication of smallpox. In young chil-
dren, eczema vaccinatum and encephalitis were serious albeit
infrequent complications. In adults, disseminated or progres-
sive vaccinia infections occurred in individuals with severe
immunodeficiency. Although very rare, these complications
represented a potential risk.
The 1980s also marked the application of recombinant
DNA technology to vaccinia virus. Recombinant gene ex-
pression by vaccinia virus was first demonstrated in 1982
[30,41]. These studies provided the means to genetically
engineer poxviruses and to develop them as expression vec-
tors and candidate vector vaccines against infectious dis-
eases. However, due to the complications observed during
smallpox vaccination, an important safety issue arose be-
cause of the possibilities of accidental laboratory infections
or side effects of vaccination, especially when using the
replicative, e.g. Western Reserve or Copenhagen, strains of
the virus. 
Two main approaches have been taken in order to
enhance the safety of vaccinia virus. One of them consists of
deleting the viral genes that are involved in viral replication,
host interactions, and/or extracellular virus formation. A sec-
ond one consists of successive passages of the virus in an
unnatural host or in tissue culture, and the isolation of viral
variants with more appropriate features.
Multiple deletions in the viral genome have led to highly
attenuated vaccinia virus strains, e.g. the NYVAC strain. This
strain was derived from the Copenhagen vaccinia virus strain
after deletion of 18 open reading frames (ORFs) of the viral
genome. Among the ORFs deleted to generate strain NYVAC
were genes involved in nucleotide metabolism, host regula-
tory functions, and viral virulence. The attenuation character-
istics of the NYVAC strain were compared in vitro and in
vivo with the parental Copenhagen strain as well as with
other vaccinia strains. The NYVAC strain was demonstrated
to be highly attenuated in many animal studies. It failed to
disseminate in immunodeficient mice and also displayed a
dramatically reduced ability to replicate on a variety of
human tissues, i.e.cultured cells. Despite these highly attenu-
ated characteristics, the NYVAC strain, as a vector, retains
the ability to induce strong immune responses to foreign anti-
gens [42].
Successive passages of the virus can also lead to safer
vaccinia viruses. The major example is the modified vaccinia
virus Ankara (MVA) strain, which was isolated after more
than 570 passages in primary chicken embryo fibroblasts.
MVA lost the ability to replicate in mammalian cells and, as
a consequence, there were no serious complications in about
120,000 recipients, including young children and aged indi-
viduals, who received the modified virus. MVA also has the
advantage, when compared with replication-competent vac-
cinia viruses, that it can be used in immunocompromised
patients. Moreover, studies using mammalian cells infected
with MVA have shown that products of both early and late
viral genes are expressed, including foreign antigens, as the
block in viral replication occurs during virion assembly
[14]. This lack of assembly of MVA makes the chance of
spreading to unvaccinated individuals or into the environ-
ment very low.
Avipoxvirus. The Avipoxvirus genus has similar charac-
teristics to all other poxviruses: a large linear dsDNA genome
of up to 300 kb, replication in the cytoplasm of infected cells,
and, importantly, the capacity to induce immunity in host
organisms. Avipoxviruses infect a number of bird species,
being named after them, e.g. fowlpox, canarypox or pigeon-
pox viruses. Wild-type strains can cause serious lesions in
their natural host species, but cannot replicate in non-avian
species. Attenuated strains of avipoxviruses, produced by
successive passages on chicken embryo fibroblasts, have
been used as vaccines for chickens and other animals for
decades. These attenuated strains are therefore recommended
in order to reduce the risk of environmental spread.
Besides being used as vectors for birds, avipoxviruses
have also been demonstrated to be efficient vehicles for
expression of foreign antigens in mammals. The inoculation
of recombinant avipoxviruses into mammalian cells results in
expression of the foreign gene in those cells, and inoculation
into the mammalian organism results in the induction of pro-
tective immunity [52]. These properties, together with the
fact that these viruses have lost the ability to replicate in non-
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avian species, have made avipoxviruses a safe and efficient
vector for inoculation of mammals. Attenuated derivatives 
of fowlpox virus, i.e. TROVAC, and canarypox virus, i.e.
ALVAC, have already been tested in a variety of species in
the veterinary field and even in human volunteers.
Construction of recombinant poxviruses. The
most common methodology for the generation of a recombi-
nant vaccinia virus is homologous recombination. Susceptible
cells are transfected with a plasmid containing the gene of
interest under the control of a vaccinia virus promoter, a
selectable marker gene or antibiotic resistance gene, and
flanking portions of nonessential vaccinia virus DNA, i.e.
thymidine kinase DNA (Fig. 2). The poxvirus promoters are
approximately 30 bp long and occur in three varieties: early,
intermediate and late. Some plasmids can combine strong
synthetic early/late tandem promoters to achieve a system
with both early and high expression levels. Co-transfection
of this plasmid and a helper wild-type vaccinia virus leads to
homologous recombination between the plasmid and the vac-
cinia genome [30]. There are a variety of methods for the iso-
lation of recombinant vaccinia viruses, including selection
based on bromo-deoxyuridine, antibiotic resistance, detec-
tion of a colored marker expression, plaque phenotype, and
DNA hybridization. Generally, the recombination occurs into
the thymidine kinase locus of the viral genome, leading to the
deletion of this gene, a process that also results in the gener-
ation of attenuated viral recombinants. 
The in vitro ligation of an exogenous gene into the vac-
cinia virus genome represents an alternative to homologous
recombination. This strategy involves cutting the vaccinia
virus DNA at a unique restriction endonuclease site, re-ligat-
ing the two halves of the genome with the recombinant gene,
and finally transfecting the ligated DNA into cells that have
been infected with the helper virus. This approach allows the
insertion of very large DNA fragments into the viral genome
[38].
Recombinant poxviruses as live vaccines. Using
some of the techniques mentioned above, recombinant pox-
viruses were initially engineered to express the protective
surface antigen of hepatitis B virus (HBV) [50], hemagglu-
tinin of influenza virus [51], envelope proteins of HIV [23]
or the circumsporozoite protein of Plasmodium knowlesi
[49]. In studies performed using those recombinants, the
capacity of vaccinia to induce T-cell responses (CD4+/CD8+)
could be shown, making these viruses good candidates as
live vaccines against infectious diseases caused by intracellu-
lar pathogens. In animals, a replicative recombinant vaccinia
virus expressing the rabies virus glycoprotein was responsi-
ble for the eradication of rabies in Belgium [3]. In humans,
the replication-deficient MVA strain is at present being tested
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Fig. 2. Construction of a recombinant vaccinia
virus and an adenovirus by homologous recombi-
nation. Vaccinia virus construction is a helper
virus-dependent system, in which a wild-type
virus incorporates the desired transgenic
sequence into the genome by means of a homolo-
gous recombination event with a plasmid vector
prepared to transfer that sequence. In contrast,
recombinant adenoviruses are mostly generated
by homologous recombination using a helper-
virus-independent system. Simultaneous transfec-
tion of two plasmids, one containing the DNA
encoding the desired antigen and one containing
the viral genome in a partially deleted non-
replicative form, is required. n, Cell nucleus.In
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for immunization against several diseases, and is one of the
preferred vehicles for antigen delivery due to its safety pro-
file. Two important diseases for which MVA vaccine research
is currently under way in humans are AIDS [11,20] and
malaria [37]. Preliminary data obtained from those studies
suggest that MVA indeed has the capacity to induce specific
T-cells against the corresponding pathogens, as was shown
previously in mice and monkeys.
Although these and other reports have highlighted the
importance of poxviral vectors as live vaccines, one major
drawback of vaccination with recombinant poxviruses, as
with other viruses for which humans are natural hosts, has to
be mentioned. Some authors observed that the capacity of
vaccinia virus to induce an immune response against heterol-
ogous proteins could be greatly impaired in recipients that
had immunity against vaccinia virus [25]. Since several vac-
cinia virus strains were used worldwide for years to eradicate
smallpox, this may become a serious concern when consider-
ing a global vaccination program. Attempts to overcome this
limitation include the use of vaccinia virus as booster
immunogens in prime-boost protocols combined with other
antigenically unrelated vectors that can prepare the immune
system for their potent effect. Those protocols are described
below.
Recombinant adenoviruses
The Adenoviridae family is divided into two genera:
Mastadenovirus and Aviadenovirus. Viruses from the
Mastadenovirus genus have the capacity to infect mammals.
Adenoviruses are medium-sized (70–100 nm), non-
enveloped icosahedral viruses containing a linear, dsDNA
genome of around 30–42 kb that does not integrate into the
host cell genome. Adenoviruses infect both dividing and rest-
ing cells of many cell types, including antigen-presenting
cells, a feature that has called much attention upon them both
as gene therapy vectors and vaccine delivery vehicles. 
There are 49 immunologically distinct adenoviral types
(6 subgenera: A–F) that can cause human infections.
Adenoviruses most commonly cause respiratory illness.
Symptoms range from the common cold syndrome to pneu-
monia, croup, and bronchitis. Some adenoviruses (eg.
serotypes 1, 2, 5, and 6) have been shown to be endemic in
regions of the world where they have been studied, and infec-
tion is usually acquired during childhood. Adenoviruses have
already been used for vaccination purposes in humans.
Serotypes 4 and 7 were used for decades to prevent acute res-
piratory syndrome (ARD) in military troops of the American
army, and whether vaccination with those viruses should be
maintained in the army vaccination program is a topic of cur-
rent discussion [22]. 
In the second half of the 1980s, the first recombinant ade-
noviruses were constructed, and the adenoviral vectors gen-
erated could replicate in many cell types. However, the
observation that removal of the E1 region of the viral genome
resulted in replication-deficient viruses led to the develop-
ment of so-called first-generation replication-deficient
recombinant vectors. Permissive cell lines, eg. human
embryonic kidney 293 cells, which complemented the func-
tions lacking in the deleted viral genomes, enabled the mul-
tiplication and purification of these recombinant viruses.
Replication-deficient adenoviruses induce self-limited infec-
tions in host organisms, representing an enormous advantage
in terms of safety, since they allow the recombinant immuno-
genic products to be expressed for just enough time to induce
an immune response.
Since the initial first-generation vectors, researchers have
developed new recombinant adenoviruses that contain less or
none (“gutless”) viral genes [53], in an attempt to limit the
immune responses generated against the vectors and to favor
their permanence in the host organisms. In addition, several
research groups have pursued vector permanence with the
aim of attaining high, sustained levels of expression of the
transgenes, mainly for gene therapy purposes. However, this
may not be necessary, and in some cases could be even prej-
udicial, when using adenoviruses as vaccines, since the
immune responses generated against the vector help to clear
the vaccine, avoiding its indefinite persistence in the organ-
ism. In addition, immune responses against the vector occur
at the same time as those against the recombinant product;
and it has been reported that the stimulation of the immune
system induced by the former could act as an adjuvant for the
latter [36].
Construction of recombinant adenoviruses.
Different methodologies were initially used to generate
recombinant adenoviruses. To date, however, most recombi-
nants constructed are based on human serotype 5 adenoviruses
by a homologous recombination approach performed either
in mammalian cells or in bacteria [21,32]. The initial work of
Frank Graham and collaborators was seminal in this case
[32]. They used two non-infectious bacterial plasmids for this
purpose, one containing the desired gene to be expressed
inside a mammalian expression cassette and flanked by ade-
noviral genomic sequences, and a second one containing the
serotype 5 adenoviral genome with regions E1 and E3 total-
ly or partially deleted to avoid viral replication and to
increase the size of foreign DNA that could be packed in the
virion (Fig. 2). After cotransfection of both plasmids, homol-
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ogous recombination between them resulted in the generation
of a new viral genome with the desired transgene inserted in
either one of the deleted regions. Viral particles could then be
purified from permissive cell lines that complemented the
function of the deleted genes. This methodology has been
further improved by the development of new plasmids that
allow faster recombinations in bacteria after including site-
specific recombination systems such as Cre/loxP or the yeast
recombinase FLP-frt system.
Recombinant adenoviruses as live vaccines. The
first studies using recombinant adenoviruses as immuniza-
tion tools were performed in the late 1980s against measles,
HIV, HBV, rabies and vesicular stomatitis virus (VSV)
[1,10,44,45]. These and subsequent studies showed that ade-
noviral vectors are extremely efficient in expressing recom-
binant products when potent promoters, eg. the immediate-
early cytomegalovirus promoter, were used to express the
transgenes. This efficiency, and the fact that adenoviral vec-
tors infect many cell types, including antigen-presenting
cells, revealed them as powerful tools for inducing cellular
immune responses. In fact, in several cases, a single immu-
nization with an adenoviral vector was enough to completely
protect host organisms against a disease. A recombinant ade-
novirus expressing the Plasmodium yoelii circumsporozoite
protein protected up to 40% of mice against experimental
malaria after only a single administration [46]. A single inoc-
ulation of a recombinant adenovirus expressing herpes sim-
plex virus (HSV) glycoprotein B also protected mice against
a lethal challenge with HSV [31].
A major obstacle for the elicitation of such potent
immune responses when adenoviruses are administered to
humans is the presence, in a large percentage of the human
population, of pre-existing immunity against the vector,
because of naturally occurring infections. With the aim of
developing new adenoviral tools that would avoid pre-exist-
ing immunity against adenovirus, several human and simian
serotypes have been recently examined as possible vehicles
for vaccine delivery. Human serotypes 2, 5 and 7 have
already been used in humans and would be excellent candi-
dates for vaccination provided that a simple blood test indi-
cated that the individual had not been pre-exposed to at least
one of these serotypes. New promising lines of research
include canine and chimpanzee-derived adenovirus vectors
to avoid pre-existing immunity against human viruses. For
example, Pinto et al. have recently shown that AdC6 and
AdC68, two simian recombinant adenoviruses expressing
HIV gag, displayed a potent capacity to induce immune
responses, even when used sequentially in prime-boost vac-
cination protocols [43].
Recombinant influenza viruses
The causative agents of the flu, influenza A viruses, are
enveloped negative-strand RNA viruses belonging to the
Orthomyxoviridae family. The genome consists of eight sin-
gle-stranded RNA segments, each encoding a single protein,
except three of the segments (NS, M and PB1), which encode
two proteins. Influenza viruses have several features that ren-
der them very promising candidates to be used as antigen-
delivery vectors [15]. First, they do not integrate into the host
genome and do not last for long periods in the host organism,
which consequently reduces the risk of potential vector-relat-
ed oncogenesis. In addition, the existence of multiple
influenza subtypes and variants allows multiple immuniza-
tions to be performed. Finally, there are attenuated viruses,
such as cold-adapted influenza strains, that are currently
under study with the aim of generating live attenuated
influenza vaccines [24,33].
Construction of recombinant influenza viruses.
The segmented nature of the influenza genome and the essen-
tially monocistronic nature of each segment has hampered
the development of recombinant viral vectors based on
influenza viruses. The development of reverse genetics tech-
niques during the last decade [40], however, has opened the
door to construction of recombinant influenza viruses able to
express heterologous sequences. Reverse genetics can be
used in helper-dependent or helper-independent systems
(Fig. 3). For the helper-dependent generation of recombinant
viruses (Fig. 3A), a bicistronic segment encoding a viral pro-
tein plus the desired antigen together with four more plas-
mids encoding each of four viral structural proteins (required
to generate the proteins that boost the formation of the new
viruses) are cotransfected into permissive cell lines.
Simultaneous infection of the cells with a wild-type influen-
za virus supplies the remaining elements necessary for the
formation of recombinant viruses. Recombinants so generat-
ed have to be then selected, a process carried out in permis-
sive cell lines, eg. MDBK. These cells take advantage of
selection features included in the recombinant bicistronic
segment, ie. the presence of a particular neuraminidase (NA)
functional only in those cells, to favor the growth of recom-
binant viruses. When using a helper-independent viral system
(Fig. 3B), a minimum of 12 plasmids have to be transfected
into the same cell in order to provide the necessary elements
to generate the new viruses. However, in this case no selec-
tion is required since the viral particles can only be generat-
ed when the recombinant bicistronic segment is included in
the viral particle.
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The first approaches to generate recombinant influenza
viruses used chimeric hemagglutinin (HA) [26] or NA [8]
carrying short foreign sequences. Such strategies enabled the
construction of influenza viruses bearing epitopes of
Plasmodium yoelli [27] or Plasmodium falciparum [34]
malaria parasites inserted into HA. Recombinant influenza
viruses carrying T-cell epitopes of lymphochoriomeningitis
virus (LCMV) virus or HSV-2 in the stalk of NA were also
generated using this methodology [2,9]. However, these
strategies suffered from the small size of the sequences that
could be inserted into HA or NA, up to 12 or 28 amino acids
respectively.
In order to express longer foreign sequences, several
attempts were made to generate bicistronic constructs encod-
ing NA or NS proteins together with the desired foreign anti-
gen. To obtain individual proteins, the IRES element of the
heavy chain of human immunoglobulin (BiP) was used as a
separator of the coding sequences. In contrast to other sepa-
rating elements tested before, BiP was functional in such
bicistronic constructs [16].
Another strategy to express longer foreign sequences by
recombinant influenza viruses was based on the replication
and packaging of a ninth independent pseudo-vRNA segment
by a wild-type influenza virus. A handicap of this strategy
consisted of the loss of this non-essential additional segment
after a few passages. However, the use of 3´-promoter
mutants with higher replication levels enabled this ninth seg-
ment to be retained in the viral progeny for more than 10 pas-
sages [28].
Finally, bicistronic influenza segments could also be con-
structed based on the observation of Flick and Hobom, who
demonstrated that the influenza polymerase complex can rec-
ognize internally located 5´and 3´promoters [13]. A pseudo-
viral segment containing two genes flanked by the 3´and
5´non-coding sequences and separated by a duplicated 3´-
promoter could be replicated and transcribed following two
modes, after interaction of the single 5′-promoter sequence
with either of the two 3′-promoter sequences. As a result,
individual proteins could be expressed by using this simpli-
fied technique. Following this strategy, Vieira-Machado et al.
explored the possibility of rescuing transfectant influenza A
viruses harboring a bicistronic NA segment with a relatively
long foreign gene, ie. the CAT protein, with a total length of
220 amino acids [29]. Recombinant influenza viruses harbor-
ing this bicistronic segment could be generated, and the syn-
thesis of the CAT protein was demonstrated. Moreover, these
recombinant viruses have been found to be genetically stable
in vitro and in vivo upon replication in the pulmonary tissue
of infected mice.
Recombinant influenza viruses as live vaccines.
One of the first diseases for which influenza recombinants
were generated and used as vaccine delivery vectors was
malaria. B- and/or T-cell epitopes from the circumsporozoite
protein (CS) of murine [27,47] and human [34] Plasmodium
parasites were inserted into influenza recombinants. CD8+
RECOMBINANT VIRUSES AGAINST INFECTIONS
Fig. 3. Recombinant influenza viruses can be generated by helper-virus-
dependent or independent methods. (A) Five plasmids have to be co-trans-
fected: one encoding the recombinant bicistronic segment or fusion protein,
and four encoding the structural proteins that would boost the formation of
new recombinant viral particles. The helper virus provides the rest of
required elements. However, by using this method, selection of the recombi-
nant viruses in permissive cells is required. (B) Using the second method
implies co-transfection of up to 17 plasmids to provide the necessary ele-
ments to generate recombinant viruses. A major advantage in this case is that
no selection of recombinants is required. n, Cell nucleus.
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T-cell epitopes from CS inserted into either NA or HA pro-
teins displayed the same efficiency in inducing a specific
immune response. Against AIDS, recombinant influenza
viruses encoding the V3 loop epitope from HIV-1 strain IIIB
also induced specific CD8+ T-cells [19]. Although specific,
most immune responses induced by recombinant influenza
viruses are of low magnitude compared to other viral vectors
and specifically to recombinant adenovirus. However, immu-
nizations with influenza recombinants have been shown to be
extremely efficient in priming immune responses that will be
further boosted by a different viral vector, ie. a vaccinia virus.
Their use as priming agents in prime-boost protocols is dis-
cussed below.
Recombinant viral vectors as 
vaccination tools in prime-boost 
protocols
In many cases, sufficient levels of cellular immunity against
a recombinant antigen could not be achieved after a single
immunization with vaccinia, adenovirus or influenza vectors.
Therefore, with the aim of enhancing the levels of T-cell
immunity induced during the primary immune response (Fig.
4A), researchers developed the so-called prime-boost immu-
nization protocols, by analogy with previous works in the
field of humoral immunity. As with antibodies, where each of
the two or three initial administrations of a purified antigen
were capable of increasing the previous levels of specific
antibodies generated against it by reactivation of the memo-
ry B-cell population, researchers hypothesized that re-expo-
sure of the immune system to the same recombinant antigens
expressed by the viral vectors should recall the memory T-
cell responses induced during the primary exposure. These
memory lymphocytes would proliferate much faster and even
acquire much higher affinity for the antigens than in previous
encounters. Nevertheless, this analogy to the situation with
antibodies turned out to be wrong. A major limitation of the
viruses as vaccine delivery vehicles was revealed: subse-
quent administrations of the same virus were cleared faster
from the organism due to immune responses induced against
the vector itself. As a consequence, the immune responses
induced against the recombinant products were barely
improved compared to those induced by the priming immu-
nizations [18,39,54] (Fig. 4B).The limitation by the anti-
vector immune responses to the re-expression of the antigen
in the host organisms did not seem to make the same virus
an optimal boost for the primary immune response. To avoid
this problem, a different viral vector expressing a common
antigen was subsequently administered (Fig. 4C). The results
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Fig. 4. Kinetics of an immune response after a single immunization with a
viral vector or after a prime-boost immunization protocol. (A) Induction of
a primary immune response. Starting from a certain number of specific naïve
circulating precursors, stimulation caused by the presence of the antigen
(delivered by recombinant virus A) in the organism activates those precur-
sors, resulting in their proliferation up to a certain level (maximum number
of activated/effector lymphocytes). Immediately after this plateau is reached,
activated lymphocytes begin to die because of lack of antigenic stimulus or
cytokines. However, long-lived memory T-cells with the same specificity
remain in the organism and will respond much faster and with much more
avidity upon a second encounter with the same antigen. (B) When the anti-
gen is presented to the immune system a second time by means of a homol-
ogous prime-boost immunization protocol using the same recombinant viral
vector (virus A + virus A), the immune response against the vector itself
(dotted line) increases rapidly, impeding an optimal re-stimulation of the
immune response against the recombinant antigen (continuous line). (C)
Heterologous prime-boost protocols using viral vectors overcome this limi-
tation. When a different viral vector (virus B) is used to re-stimulate the pri-
mary immune response (virus A), the immune response against the previous
vector does not interfere with the new one, and thus the immune response
against the recombinant product can be fully re-stimulated.
of several studies on malaria vaccine development by
Zavala, Nussenzweig and collaborators [5,18,27,34,39,47]
showed that greatly enhanced immune responses could be
obtained when two viral vectors were used following the
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same prime-boost immunization protocol. For example, a
vaccinia virus expressing Plasmodium yoelii CS was able to
increase more than 20-fold the number of CS-specific IFNγ-
producing CD8+ T-cells induced by an influenza recombi-
nant virus [27]. The sequence of administration of the vec-
tors seemed to be of enormous importance. In fact, the
immune responses induced by the vaccinia virus adminis-
tered first could not be enhanced by the later administration
of the influenza recombinant vector. Moreover, infection of
mice with recombinant adenovirus, influenza virus, or an
attenuated cold-adapted influenza virus, expressing all or
parts of the CS protein of Plasmodium spp., were strongly
enhanced by the subsequent administration of vaccinia
recombinants derived either from the WR replicative or
from the replication-deficient MVA strains. As an example,
Fig. 5 shows representative results of our previous and of
ongoing work using recombinant vectors, eg. DNA vaccines
and viral vectors, encoding the CS protein of the murine
malaria parasite Plasmodium yoelii. The number of IFNγ-
producing CD8+ T-cells induced in mice immunized with
the different delivery vectors, regardless of their plasmidic
or viral nature, is substantially enhanced when prime-boost
protocols are used to immunize the animals. However, Fig.
5 shows that a prime-boost protocol using exclusively viral
vectors induces much greater immune responses than com-
binations of plasmid DNA vaccines and viral vectors. In all
these studies, protection against malaria also increased after
the boost, and elicited sterile protection against malaria in
100% of the animals when they were primed with a recom-
binant adenovirus or a cold-adapted influenza virus and
boosted with recombinant WR or MVA vaccinia viruses
respectively [5,18].
Several studies in other fields confirmed the capacity of
poxviruses as powerful boosting agents of primary immune
responses induced by other viral vectors. Thus, vaccinia
viruses have been used extensively as boosters of the
immune responses induced by other recombinant vectors
encoding HIV proteins. A vaccinia recombinant encoding
HIV-1 env protein was able to increase between five- and six-
fold the immune response induced by a recombinant influen-
za virus encoding the CD8+ T-cell epitope contained in the
V3 loop of this protein [19]. Moreover, even higher specific
cellular immune responses directed against the same protein
could be detected when the prime immunization with the
recombinant influenza virus was followed by a boost immu-
nization with a recombinant MVA virus [17,19], including at
sites where the immune response against the virus is funda-
mental for protection, such as lymph nodes that drain genital
and rectal tracks. 
Recently, it has been shown that vaccinia virus may not
be the only powerful boosting vector. Thus, one of the most
promising recent approaches for AIDS vaccine development
using viral vectors has been the immunization of monkeys
with DNA vaccines as priming agents followed by aden-
ovirus or a MVA recombinant as boosters [6,7,48]. In these
studies, the adenoviral vector seemed to induce a better boost
compared to MVA, eliciting high levels of protection against
infection with a pathogenic simian-human hybrid AIDS virus
RECOMBINANT VIRUSES AGAINST INFECTIONS
Fig. 5. Plasmodium yoelii circumsporozoite (CS)-specific IFNγ-producing
CD8+ T-cells induced in animals immunized with different recombinant
vectors encoding the CS protein. Animals were immunized with individual
vectors or sequential combinations in the so-called prime-boost protocols as
indicated. D, DNA plasmid immunization I
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in all immunized animals. However, further studies are need-
ed to confirm this conclusion. 
Prime-boost protocols have also been demonstrated to be
extremely useful to overcome some of the problems of pre-
existing immunity to viral vectors. Thus, using a different
vector, eg. DNA vaccines [54], to prime the immune respons-
es to an antigen also encoded by a recombinant adenovirus or
a recombinant MVA virus, these vectors were capable of pro-
viding a strong boost to the initial immune response in ani-
mals with pre-existing immunity against them.
In conclusion, viral vectors are promising tools to induce
cellular immune responses against diseases caused by intra-
cellular parasites. Since vaccination against these diseases
will be difficult to achieve by immunization with purified
antigens or even DNA vaccines, prime-boost immunization
protocols using recombinant viral vectors that encode protec-
tive antigens alone or in combination with any of the other
antigen-delivery systems have a great potential to accomplish
this goal. The ongoing work in this field is providing new
perspectives as to how to deal with infections caused by
intracellular microbes, and, hopefully, one of the clinical trials
under way will soon result in the first human vaccination pro-
gram to include recombinant vectors as immunizing agents.
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Uso de virus recombinantes para inducir inmunidad
celular contra enfermedades infecciosas
Resumen. Las infecciones por patógenos intracelulares como virus, algu-
nas bacterias y numerosos parásitos son neutralizadas en la mayoría de los
casos tras la activación de respuestas inmunitarias específicas mediadas por
linfocitos T, que reconocen los antígenos extraños y eliminan las células
infectadas. Las vacunas contra estos organismos infecciosos se han basado
tradicionalmente en la administración de organismos enteros atenuados o
inactivados. Actualmente la investigación se centra en el desarrollo de va-
cunas compuestas por subunidades que contengan los antígenos más inmu-
nogénicos para cada patógeno particular. No obstante, si se administran vac-
unas de subunidades purificadas mediante los protocolos tradicionales de
inmunización,  los niveles inducidos de inmunidad celular son en su mayoría
bajos e incapaces de generar una protección completa contra las enfer-
medades causadas por los microorganismos intracelulares. En esta revisión
presentamos una prometedora alternativa a estos métodos tradicionales
mediante el uso de virus recombinantes cuyo genoma codifica las sub-
unidades de vacuna. Los virus recombinantes reúnen varias características
que los hacen muy eficientes para inducir las respuestas inmunitarias medi-
adas por los linfocitos T. Recientemente se ha demostrado que la inmunidad
celular es crucial en la protección contra la malaria y el SIDA, que son un
objetivo prioritario de la Organización Mundial de la Salud en cuanto al
desarrollo de vacunas. Por lo tanto, esta revisión se centra especialmente en
el desarrollo de nuevos protocolos de vacunación contra estas dos enfer-
medades. [Int Microbiol 2004; 7(2):83–94]
Palabras clave: adenovirus · virus vaccinia · virus de la gripe · vacunas ·
linfocitos T
O uso vírus recombinantes na indução de imunidade
celular protetora contra doenças infecciosas
Resumo. As infecções causadas por patógenos intracelulares como os
vírus, algumas bactérias e muitos parasitas terminam, em muitos casos, após
ativação de respostas imunes de células T específicas, as quais reconhecem
os antígenos estranhos e eliminam as células infectadas. As vacinas contra
esses microorganismos infecciosos foram tradicionalmente desenvolvidas
através da administração dos micróbios completos vivos ou atenuados. Hoje
em dia, a pesquisa em vacinas de subunidade contendo os antígenos mais
imunogênicos desses patógenos é a principal escolha para as doenças contra
as quais não existem vacinas. Porém, quando as vacinas de subunidade são
administradas seguindo os protocolos tradicionais de imunização, os níveis
de imunidade celular induzidos são comumente baixos e incapazes de gerar
proteção completa contra as doenças causadas pelos microorganismos
intracelulares. Nesta revisão apresentamos uma alternativa promissora aos
protocolos tradicionais, que é o uso como ferramentas de vacinação de
vetores virais recombinantes que codificam vacinas de subunidade. Os vírus
recombinantes têm várias características interessantes que os tornam
extremamente eficientes na indução de respostas imunes mediadas por lin-
fócitos T. Durante os últimos anos, observou-se que esta imunidade celular
tem importância fundamental para a proteção contra duas doenças que são
objetivos primordiais da Organização Mundial da Saúde: a malária e a
AIDS. Por esses motivos esta revisão focaliza especialmente o desenvolvi-
mento de novos protocolos de vacinação contra estas duas doenças. [Int
Microbiol 2004; 7(2):83–94]
Palavras chave: adenovírus · vírus vaccinia · vírus da gripe · vacinas ·
linfócitos T
